A Phase 2 interventional study of Mirikizumab - Intravenous (IV) and Mirikizumab - Subcutaneous (SC) in Colitis, Ulcerative and Crohn Disease, sponsored by Eli Lilly and Company. Recruiting at 71 sites in 10 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Colitis, Ulcerative by Eli Lilly and Company — 5 open to participants now, 7 under way, 3 of them phase 3. Colitis, Ulcerative · Eli Lilly and Company.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 13th largest by planned enrollment, is one of 2 that started in 2026, is one of 8 in phase 2, and was the 16th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 16 studies in Colitis, Ulcerative by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Brazil and 25 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Brazil and 14 more countries
Ages 18–80
Eli Lilly and Company · Sites in United States, Austria, Belgium and 20 more countries
Ages 18–70
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 211 across the 16 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
2 of the studies in Colitis, Ulcerative by Eli Lilly and Company that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07186101Eli Lilly and CompanyLY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: | 2027-05 |
| NCT07483073Eli Lilly and CompanyA Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study IIBD is a master protocol that will support a collection of individual sub studies that share key design components. Participants will be assigned to the appropriate study prior to randomization to a treatment group. The studies aim to evaluate the efficacy and safety of new treatments in adults with moderately to severely active ulcerative colitis or Crohn's disease and will last at least 62 weeks.
The criteria were revised on the registry on Oct 22, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For UC:
For CD:
Exclusion Criteria:
Must not have a current diagnosis of inflammatory bowel disease (IBD)-unclassified or primary sclerosing cholangitis
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study Period 1: mirikizumab administered via IV. Study Period 2: Responders will receive mirikizumab SC.
Drug: Mirikizumab - Intravenous (IV) · Drug: Mirikizumab - Subcutaneous (SC)
Study Period 1: Co-administration of LY4395089 administered orally and mirikizumab administered IV. Study Period 2: Responders will stop LY4395089 and receive mirikizumab SC.
Drug: Mirikizumab - Intravenous (IV) · Drug: Mirikizumab - Subcutaneous (SC) · Drug: LY4395089
Administered IV
Also known as: LY3074828
Administered SC
Also known as: LY3074828
Administered orally
Number of Participants Allocated to Each of the Intervention-Specific Appendices (ISA)
Time frame: Baseline, Up to Day 42
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal should be approved by an independent review panel and researchers should sign a data sharing agreement.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 13 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LY4395089